Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabotamig (ARB202) in Advanced Gastrointestinal Malignancies
NCT05411133Phase 1Completed
- Sponsor
- Arbele
- Start
- May 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of cabotamig in gastrointestinal cancer, cholangiocarcinoma (CCA), liver cancer and 6 more (5 arms), sponsored by Arbele. Primary endpoint: Incidence and severity of adverse events at 8 weeks. Started May 2022; status: completed.
02
Drugs
cabotamig
03
Conditions
gastrointestinal cancercholangiocarcinoma (CCA)liver cancercolorectal adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05411133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411133.